Joshua T. Brumm
See Remarks at Dyne Therapeutics Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: Dyne Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Dyne Therapeutics Inc. May 24, 202384.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 18, 2026 | Crescent Biopharma Inc. | Open-market sale | −7,837 | $16.71 | $130,956 |
| Sep 16, 2026 | Crescent Biopharma Inc. | Open-market sale | −1,610 | $17.90 | $28,819 |
| Jun 22, 2026 | Crescent Biopharma Inc. | Open-market sale | −42,305 | $17.99 | $761,067 |
| Dec 15, 2025 | Crescent Biopharma Inc. | Grant or award | +45,117 | — | — |
| Dec 15, 2025 | Crescent Biopharma Inc. | Grant or award | +10,000 | — | — |
| Mar 11, 2024 | Dyne Therapeutics Inc. | Option exercise | +50,000 | $5.54 | $277,000 |
| Mar 11, 2024 | Dyne Therapeutics Inc. | Open-market sale | −40,072 | $25.42 | $1,018,630 |
| Mar 11, 2024 | Dyne Therapeutics Inc. | Open-market sale | −9,928 | $26.10 | $259,121 |
| Mar 11, 2024 | Dyne Therapeutics Inc. | Open-market sale | −7,769 | $26.12 | $202,926 |
| Mar 11, 2024 | Dyne Therapeutics Inc. | Open-market sale | −8,618 | $25.93 | $223,465 |
| Mar 8, 2024 | Dyne Therapeutics Inc. | Option exercise | +153,931 | $5.54 | $852,778 |
| Mar 8, 2024 | Dyne Therapeutics Inc. | Option exercise | +209,412 | $5.54 | $1,160,142 |
| Mar 8, 2024 | Dyne Therapeutics Inc. | Open-market sale | −202,238 | $25.30 | $5,116,621 |
| Mar 8, 2024 | Dyne Therapeutics Inc. | Open-market sale | −160,670 | $26.72 | $4,293,102 |
| Mar 8, 2024 | Dyne Therapeutics Inc. | Open-market sale | −435 | $27.38 | $11,910 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.